Sign in
WithdrawnNo phase

A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)

Key facts

Who runs it
Takeda
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
30 Jan 2024
Ended
30 Dec 2024
Type of study
Observational, 2 groups
Record updated
23 October 2023
Why it stopped
Business reason, unrelated to product safety

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Cohort 1 and 2:
  • Participants with a diagnosis of locally advanced or metastatic NSCLC, clinical staging of IIIB-IV; Cohort-1:
  • Participants who have received NGS testing and have EGFR ex20ins positive result; Cohort-2:
  • Participants who have received NGS testing

Who cannot take part

  • Incomplete information, including key demographic characteristics, clinicopathological characteristics, and genetic testing information

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main aim of this study is to examine the percentage of people with lung cancer who carry a certain gene mutation (epidermal growth factor receptor exon 20 insertions - EGFR ex20ins) and their frequency in Chinese participants with Non-small cell lung cancer (NSCLC) after having been tested for the gene mutation.

Read full original descriptionShow less

Data from the participant's electronic medical records at the hospital will be collected.

The 2 groups in the trial

  • Cohort 1: Participants With Positive EGFR ex20ins Detection

    Participants with NSCLC having positive EGFR ex20ins detected by NGS were observed retrospectively for three years prior to leading site initiation.

  • Cohort 2: Participants With Positive and Negative EGFR ex20ins Detection

    Participants with NSCLC having positive and negative EGFR ex20ins NGS testing results were observed retrospectively for three years prior to leading site initiation.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
To Investigate EGFR Exon20 Insertion Mutation Testing Methodologies, Clinicopathological Characteristics and Molecular Epidemiology in Chinese Patients With Advanced NSCLC: a Nationwide Multicentre Real-world Registry Study
Record updated
23 October 2023